CNBX Pharmaceuticals Inc., an early-stage biotechnology company based in Bethesda, Maryland, is making strides in the Health Care sector, specifically within the Pharmaceuticals industry. The company is dedicated to the development and licensing of cannabinoid-based treatments and therapies, aiming to revolutionize the use of cannabis in treating various ailments and enhancing patients’ quality of life.
As of May 18, 2026, CNBX Pharmaceuticals Inc. is listed on the OTC Bulletin Board, with a close price of $0.00015. The company’s market capitalization stands at $295,150 USD, reflecting its position as a small-cap entity within the biotechnology landscape. Over the past year, the stock has experienced significant volatility, with a 52-week high of $0.0063 recorded on July 1, 2025, and a 52-week low of $0.0001 as of May 18, 2026.
The company’s financial metrics indicate a challenging environment, as evidenced by a negative price-to-earnings ratio of -0.53. This suggests that CNBX Pharmaceuticals Inc. is currently not generating profits, which is not uncommon for early-stage biotech firms focused on research and development.
CNBX Pharmaceuticals Inc. is committed to exploring the therapeutic potential of cannabinoids, a class of compounds found in cannabis. The company’s research efforts are directed towards identifying novel applications of these compounds in medical treatments, with the goal of addressing unmet medical needs and improving patient outcomes.
The strategic focus on cannabinoid-based therapies positions CNBX Pharmaceuticals Inc. at the forefront of a rapidly evolving field within the pharmaceutical industry. As regulatory landscapes and public perceptions of cannabis continue to shift, the company’s innovative approach could potentially lead to significant advancements in medical treatments.
In summary, CNBX Pharmaceuticals Inc. is a small-cap biotechnology company with a clear mission to harness the therapeutic potential of cannabinoids. Despite current financial challenges, the company’s focus on pioneering treatments in the cannabis space may offer promising opportunities for future growth and impact in the healthcare sector.
